Navigation Links
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
Date:7/1/2009

ollitropin beta). A total of 1,506 patients (greater than 60 kg) at 34 IVF clinics in North America and Europe were randomized to receive either corifollitropin alfa 150 mcg or a daily dose of 200 IU rFSH, followed by rFSH (maximum 200 IU/day) from stimulation day eight onward, when required. Starting on stimulation day five, all patients received 0.25 mg gonadotropin-releasing hormone (GnRH) antagonist until triggering of final oocyte maturation by human chorionic gonadotropin (hCG). The primary endpoint was the ongoing pregnancy rate assessed at ten weeks or more after embryo transfer. The number of oocytes retrieved was the co-primary endpoint. The incidence of ovarian hyperstimulation syndrome (OHSS) was similar between both groups, 7.0 percent in the corifollitropin alfa group (1.9 percent severe) and 6.3 percent in the follitropin beta group (1.3 percent severe).(1)

Key Findings

  • The ongoing pregnancy rate in the 150 mcg corifollitropin alfa treatment arm (38.9 percent per started cycle) was similar to that achieved in patients receiving daily 200 IU rFSH (follitropin beta) (38.1 percent per started cycle).(1)
  • Corifollitropin alfa achieved similar efficacy regardless of fertilization procedure; number of embryos transferred; or day of embryo transfer;(1) as detailed in the table below:

                         Overall  IVF   ICSI   Single Double  Day 3  Day 5
                         N=1506  N=481  N=830  N=363  N=1013  N=850  N=506
    Corifollitropin alfa  38.9%  36.5%  39.7%  34.7%  46.9%   41.7%  47.1%
    rFSH                  38.1%  35.4%  40.3%  28.9%  44.9%   35.1%  50.6%

  • The mean number of oocytes retrieved per attempt was 13.7 (+/-8.2) for the corifollitropin alfa group and 12.5 (+/-6.7) for the rFSH group.(2)
  • The mean number of good quality embryos obtained at day 3 and
    '/>"/>

SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... in the Nation ,, PHILADELPHIA, Dec. 16 ... has been granted Magnet(R) recognition by the American ... is one of the highest levels of recognition ... places Hahnemann among the five percent of hospitals ... distinction. ,, At 9:00 am on Monday, Hahnemann ...
(Date:12/16/2009)... -- Decision Resources, one of the world,s leading ... issues, finds that, according to responses from surveyed ... (both interleukin inhibitors) will capture 22 percent of ... market for moderate to severe psoriasis. Among these ... nearly three times as much patient share as ...
(Date:12/16/2009)... for the ultimate CHO cell culture supplement? InVitria has what ... cell culture media supplement that improves the growth and productivity ... culture performance, Zap-CHO is an animal free, well defined and ... ... Fort Collins, CO (PRWEB) December 16, 2009 -- Scientists working ...
(Date:12/15/2009)... MARINO, Calif., Dec. 15 Epeius Biotechnologies ... targeted genetic medicine, gained international validation of the ... Rexin-G , when scientists around the world rediscovered ... a major locus of cancer pathogenesis and disease ... therapies. Recently, scientists at the NIH National Cancer ...
Breaking Biology Technology:Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3Online Video of InVitria's Zap-CHO Helps Scientists Maximize CHO Cell Culture Performance 2Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3
... Orexigen(R) Therapeutics,Inc. (Nasdaq: OREX ), a biopharmaceutical company ... obesity, today announced,that the Company will be presenting at ... the Biotech Industry Thursday, September 4, 2008, 10:00 ... UBS Global Life Sciences Conference Tuesday, September ...
... Mass., Aug. 28 RainDance Technologies, Inc.,a provider ... research, today announced a collaboration with the Scripps,Translational ... as a solution to a key bottleneck in ... support STSI in its exciting effort to discover,inherited ...
... 28 Barr Pharmaceuticals,Inc. (NYSE: BRL ) ... final approval from the U.S. Food & Drug ... of Ortho McNeil Janssen,s,Razadyne(R) (galantamine hydrobromide), 4 mg, ... launch its generic Razadyne tablets product immediately., ...
Other Biology Technology:RainDance and Scripps to Collaborate on Targeted Sequencing for 'Wellderly' Study 2RainDance and Scripps to Collaborate on Targeted Sequencing for 'Wellderly' Study 3RainDance and Scripps to Collaborate on Targeted Sequencing for 'Wellderly' Study 4RainDance and Scripps to Collaborate on Targeted Sequencing for 'Wellderly' Study 5Barr Receives Approval for Generic Version of Razadyne(R) Tablets 2Barr Receives Approval for Generic Version of Razadyne(R) Tablets 3Barr Receives Approval for Generic Version of Razadyne(R) Tablets 4Barr Receives Approval for Generic Version of Razadyne(R) Tablets 5
(Date:12/16/2009)... 7 IgeaCare Solutions Inc. is pleased ... the healthcare communications company previously operating as IgeaCare ... now move forward under new leadership and funding. ... Rochon to the position of Chief Executive Officer. ... on providing a superior servicing and support model; ...
(Date:12/16/2009)... CSC (NYSE: CSC ... for Laboratory Accreditation awarded the International Organization ... to the company,s Test Lab, which is ... in Fairmont, W.Va. The Test Lab is ... world to achieve this accomplishment. ,, ...
(Date:12/15/2009)... Mo. As soon as babies are born, ... jaundice and e-coli. For up to a month, their ... these infections are often minor, they can lead to ... immune systems, University of Missouri researchers have pinpointed a ... to an immune-strengthening vaccine. , "We,re trying to improve ...
Breaking Biology News(10 mins):IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2Researchers work on vaccine to improve immune system in newborns 2Post transplant combo can replace toxic immune suppressing drugs in monkeys 51106 1Post transplant combo can replace toxic immune suppressing drugs in monkeys 51106 2Springer launches SpringerImages 9172 1Springer launches SpringerImages 9172 2LoJack SafetyNet and Project Lifesaver Help Rescue Clients Afflicted With Alzheimers Dementia Who Wandered 51100 1LoJack SafetyNet and Project Lifesaver Help Rescue Clients Afflicted With Alzheimers Dementia Who Wandered 51100 2LoJack SafetyNet and Project Lifesaver Help Rescue Clients Afflicted With Alzheimers Dementia Who Wandered 51100 3LoJack SafetyNet and Project Lifesaver Help Rescue Clients Afflicted With Alzheimers Dementia Who Wandered 51100 4LoJack SafetyNet and Project Lifesaver Help Rescue Clients Afflicted With Alzheimers Dementia Who Wandered 51100 5
... Through studying pigeons with genetic heart disease, researchers at ... clue about why some patients' heart vessels are prone ... identified a regulator of genes that controls the growth ... senior researcher. "Learning to modulate the uncontrolled growth of ...
... A Northwestern University research group has discovered that ... is critical to proper embryo formation. , ... in the advanced online issue of the journal ... unstable embryonic growth factor by injecting aggressive melanoma ...
... Methylphenidate (Ritalin) elevates norepinephrine levels in the brains ... nerve signal transmissions in the sensory pathways to ... a Philadelphia research team has found. , Their ... how a stimulant aids people with attention deficit ...
Other Biology News:Pigeons provide clue to solving common problem in heart patients 2Malignant melanoma cells secrete protein required for embryo formation 2Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 2Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 3